Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.

Clinical colorectal cancer

Volumn 5, Issue 3, 2005, Pages 188-196

  Kupsch, Petra ^a   Henning, Bernhard F ^a   Passarge, Katrin ^a   Richly, Heike ^a   Wiesemann, Katrin ^a   Hilger, Ralf A ^a   Scheulen, Max E ^a   Christensen, Olaf ^a   Brendel, Erich ^a   Schwartz, Brian ^a   Hofstra, Elke ^a   Voigtmann, Rudolf ^a   Seeber, Siegfried ^a   Strumberg, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; OXALIPLATIN; PLATINUM COMPLEX; PYRIDINE DERIVATIVE; SORAFENIB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PYRIDINES;

EID: 32944478104     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.030     Document Type: Article

References (0)